Participant disposition. ∗ indicates that emicizumab dose was up-titrated in 1 participant on day 374 while starting the long-term follow-up period. Up-titration was per investigator request based on locally assessed decreasing emicizumab levels (confirmed retrospectively to be 6.6 μg/mL in a central assessment). This participant experienced 3 treated and 2 untreated bleeds (all traumatic) before and after up-titration, respectively. † indicates that bleed end points consider data before up-titration only. Q2W, every 2 weeks; Q4W, every 4 weeks; QW, weekly.